Supplementary Tables 1-5: Optimum immunotherapy method according to PD-L1 expression in advanced lung cancer: a network meta-analysis

Supplementary Table 1. Optimum immunotherapy method according to PD-L1 expression in advanced lung cancer: a network meta-analysisBayesian ranking results of network meta-analysis. PlaCT= platinum-based chemotherapy. &lt;1%=patients with PD-L1 expression less than 1%; 1-49%=PD-L1 expression is greater than 1% and less than 50%; ≥50%=PD-L1 expression more than or equal to 50%.<br>Supplementary Table 2. Optimum immunotherapy method according to PD-L1 expression in advanced lung cancer: a network meta-analysisBayesian ranking results in patients previously untreated, in patients receiving checkpoint inhibitors monotherapy or combination therapy subgroups. The number in each cell represents the posterior probability of the row-defining treatment being ranked at the column defining position. PlaCT= platinum-based chemotherapy. &lt;1%=patients with PD-L1 expression less than 1%; 1-49%=PD-L1 expression is greater than 1% and less than 50%; ≥50%=PD-L1 expression more than or equal to 50%.<br>Supplementary Table 3. Optimum immunotherapy method according to PD-L1 expression in advanced lung cancer: a network meta-analysisBayesian ranking results in patients with advanced lung cancer receiving PD-1 inhibitors or PD-L1 inhibitors subgroup. The number in each cell represents the posterior probability of the row-defining treatment being ranked at the column defining position. &lt;1%=patients with PD-L1 expression less than 1%; 1-49%=PD-L1 expression is greater than 1% and less than 50%; ≥50%=PD-L1 expression more than or equal to 50%. immunotherapy= immune checkpoint inhibitor; Prior+chem=previously treated with platinum-based chemotherapy.<br>Supplementary Table 4. Optimum immunotherapy method according to PD-L1 expression in advanced lung cancer: a network meta-analysisBayesian ranking results for patients with PD-L1 TPS&lt;1%, TPS 1-49% and TPS≥50% subgroups. Platinum=platinum-based chemotherapy.<br>Supplementary Table 5. Optimum immunotherapy method according to PD-L1 expression in advanced lung cancer: a network meta-analysisI2 values and Comparisons of the fit of consistency and inconsistency models using deviance information criteria (DIC).<br>